Cantor Fitzgerald Remains Bullish on Perrigo (PRGO) Despite Guidance Cut
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Revolution Medicines prices RASONQUE at $39,800 per month
Perrigo Co. (PRGO) PT Lowered to $67 at RBC Capital
August 10, 2018 9:07 AM EDTRBC Capital lowered its price target on Perrigo Co. (NYSE: PRGO) to $67.00 (from $89.00) while maintaining a Sector Perform rating.
... MorePerrigo (PRGO) Tops Q2 EPS by 3c, FY EPS Guidance Misses Views
August 9, 2018 6:19 AM EDTPerrigo (NYSE: PRGO) reported Q2 EPS of $1.22, $0.03 better than the analyst estimate of $1.19. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.23 billion.
GUIDANCE:
Perrigo sees FY2018 EPS of $4.75-$4.95, versus the consensus of $5.20.
For earnings history and earnings-related data on Perrigo (PRGO) click here.
... MorePerrigo (PRGO) to Separate Prescription Pharmaceuticals Business
August 9, 2018 6:17 AM EDTPerrigo Company plc (NYSE: PRGO) today announced that its Board of Directors approved a plan to separate the Company's Prescription Pharmaceuticals (Rx) business following the Company's previously announced strategic portfolio review. Continuing its focus on enhancing shareholder value, the Board believes a separation of the Rx business will better enable this unique asset to capitalize on its platform of differentiated generic pharmaceutical products and allows Perrigo to focus on expanding its leading consumer business. The Board will consider all value-enhancing options, including a possible tax-efficient separation to shareholders, a sale or... More
Perrigo plans to separate prescription pharma business
August 9, 2018 1:04 AM EDTBy Tamara Mathias
(Reuters) - Perrigo Co Plc (NYSE: PRGO) said on Thursday it would separate its generics prescription business, which has been a drag on results, to focus on consumer healthcare following a strategic review, sending the drugmaker's shares down about 8 percent.
Generic drugmakers such as Perrigo, Mylan (NASDAQ: MYL) and Teva Pharmaceutical Industries (NYSE: TEVA) have suffered over the past few years as price erosion has pressured... More
